Increasing incidence of cancer and rising number of patients showing response failure to alternative treatments is expected to foster growth of the...
News
Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
On January 3, 2019, Takeda announced multiple research collaborations involving the development of chimeric antigen receptor T-cell (CAR-T)...
Latest technology can identify Multiple Myeloma cells faster than ever
Multiple myeloma is a type of blood cancer that affects the plasma cells located in the bone marrow of the body. During an infection, when B cells...
Multiple Myeloma Drugs Market: How Will Be the Industry Growth by 2023
The 'Global and Southeast Asia Multiple Myeloma Drugs Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the...
Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma
Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or...
Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma
The anti-BCMA CAR T-cell therapy bb21217 demonstrated an objective response rate (ORR) of 83.3%, with a very good partial response (VGPR) or better...
Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing
AIMS: Multiple myeloma is a genomically complex haematological malignancy with many genomic alterations recognised as important in diagnosis,...
New drug improves survival in multiple myeloma patients: Lancet
A therapeutic drug, called lenalidomide, has shown improved outcomes and survival rates in patients with a serious type of bone marrow cancer...
Jagannath Discusses Building on the Biology of Multiple Myeloma
Understanding the proliferation of malignant myeloma cells can only be discerned by going back to the biology of the disease, explained Sundar...
CAR T-cell therapy cost-effective compared with past treatments
Chimeric antigen receptor T-cell therapy has improved health outcomes at a more cost-effective rate than other cancer treatments, according to a...
Innovative cancer research gets a $600k leg up from Kiwi Freemasons
A New Zealand research team on the cusp of a cancer breakthrough has been gifted a significant financial boost thanks to the world's oldest...
Anti-BCMA CAR T Cell Development Continues to Evolve for Multiple Myeloma
Each of the many BCMA-targeted chimeric antigen receptor (CAR) T cells in development demonstrate a different efficacy and safety profile, and each...